Avenzo Therapeutics
PrivateLast Round
Private Placement
Jun 1, 2026
Est. Valuation
$515M
Total Funding Raised
$792.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Avenzo Therapeutics is a biotechnology company that develops next-generation oncology therapies, including small-molecule inhibitors and antibody-drug conjugates, for patients with cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avenzo Therapeutics Comparables
Compare Avenzo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incyclix Bio | 86% | |
| NiKang Therapeutics | 81% | |
| Pyxa Pharmaceuticals | 80% |
For institutional investors. Book with your work email.
Avenzo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 1, 2026 | ||||
| Series B | Sep 22, 2025 | ||||
| Series A | Nov 18, 2024 | ||||
| Series A Extension | Mar 26, 2024 | ||||
| Series A | May 25, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Avenzo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Private Placement, Series A Extension, Series A, Series B |
| New Enterprise Associates | Private Placement, Series B, Series A Extension, Series A |
| TF Capital | Series A Extension, Series A, Series B |
| 渶策资本 | Series A Extension, Series A, Series B |
| Deep Track Capital | Private Placement, Series B, Series A Extension, Series A |
| OrbiMed | Private Placement, Series A Extension, Series A, Series B |
| Foresite Capital | Private Placement, Series A Extension, Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 80% MoM, reaching 7.7K.
- Jun 1, 2026
$215M round with participation from NEA and Blackstone.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 30, 2026
Avenzo Therapeutics, Inc. is to present preliminary Phase 1 results from the ORION-1 study of AVZO-023, a selective CDK4 inhibitor, at the 2026 San Antonio Breast Cancer Symposium in Texas.
- attends_eventOct 30, 2026
Avenzo Therapeutics, Inc. plans to present preliminary Phase 1 results from the ORION-1 study of AVZO-023, a selective CDK4 inhibitor, at the 2026 San Antonio Breast Cancer Symposium.
- goes_publicOct 1, 2026
Avenzo Therapeutics, Inc. appoints Annie Chang as senior vice president of investor relations and corporate communications to join its executive leadership ahead of its anticipated IPO.
- hiresSep 28, 2026
Avenzo Therapeutics, Inc. appoints Aaron Hasnain as Senior Vice President, Business Development, and he serves on its executive leadership team in California on Sep 28th '26.
- hiresSep 3, 2026
Avenzo Therapeutics, Inc. appoints Barbara Bodem as an independent director alongside Elizabeth Mily, adding more than 60 years of combined healthcare, finance and business development experience to its board in California on Sep 3rd '26.
For institutional investors. Book with your work email.
Avenzo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Avenzo Therapeutics's valuation, stock price, and market status.
Is Avenzo Therapeutics a public or private company?
Avenzo Therapeutics is a private company.
What is the current stock price of Avenzo Therapeutics?
Avenzo Therapeutics is a private company, so its shares have no public market price. Caplight tracks Avenzo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Avenzo Therapeutics worth (valuation)?
Avenzo Therapeutics's valuation is estimated at $515.0M based on funding round data.
Can I buy Avenzo Therapeutics stock?
Avenzo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Avenzo Therapeutics's last funding round?
Avenzo Therapeutics's most recent funding round was Private Placement on June 1, 2026.
Who are the main investors in Avenzo Therapeutics?
Key investors in Avenzo Therapeutics include New Enterprise Associates, Deep Track Capital, OrbiMed, SR One, Sands Capital.
Will Avenzo Therapeutics IPO soon?
No public IPO plans have been announced for Avenzo Therapeutics.
How can I track Avenzo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Avenzo Therapeutics's shares on secondary markets.